Skip to content

Study · Non-randomized trial · n = 18 · 1990

3 results

A comparison of the acute effects of subcutaneous and intranasal calcitonin.

O'Doherty DP, Bickerstaff DR, McCloskey EV, Atkins R, Hamdy NA, Kanis JA

Clinical science (London, England : 1979)1 Feb 1990Cited by 14 (Europe PMC)

PMID2155751 (opens in a new tab)DOI10.1042/cs0780215 (opens in a new tab)PepBankPUB-02155751
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Paget's disease, subcutaneous salmon calcitonin caused a dose-dependent serum calcium fall, absent with placebo.

    In plain wordsIn Paget's disease, injected salmon calcitonin lowered blood calcium in a dose-dependent manner, unlike placebo.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseSerum calcium
    Study

    n = 18

    Comparator
    Placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    1, 10 and 100 units · subcutaneous · single doseAs given in this study (human).

    Source sentences

    Summary
    Subcutaneous salmon calcitonin, administered at doses of 1, 10 and 100 units to nine patients with Paget's disease of bone, induced a dose-dependent fall in the serum calcium.
    3 context sentences
    Summary · context
    This calcium-lowering effect was not seen with a second group of nine patients receiving placebo.
    Summary · context
    We studied the acute effects of intranasal and subcutaneous calcitonin in 40 patients with active Paget's disease of bone.
    Summary · context
    Patients received a single dose of either 400 units of calcitonin delivered as a nasal spray, or 1, 10 or 100 units of subcutaneous calcitonin, or placebo.
  2. 02HumanNon-randomized trialEfficacy outcome

    In Paget's disease, lower calcitonin doses had significant effects that were greater in patients with lower bone turnover.

    In plain wordsIn Paget's disease, lower calcitonin doses had greater effects in patients with lower bone turnover.

    Peptide
    Calcitonin-salmon
    Outcome
    Direction not reportedEffects of lower calcitonin doses by bone turnover rate
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    lower doses · single doseAs given in this study (human).

    Source sentences

    Summary
    The lower doses of calcitonin had significant effects, and these were more pronounced in patients with lower rates of bone turnover.
    2 context sentences
    Summary · context
    We studied the acute effects of intranasal and subcutaneous calcitonin in 40 patients with active Paget's disease of bone.
    Summary · context
    Patients received a single dose of either 400 units of calcitonin delivered as a nasal spray, or 1, 10 or 100 units of subcutaneous calcitonin, or placebo.
  3. 03HumanNon-randomized trialEfficacy outcome

    In Paget's disease, 400 units of nasal calcitonin had efficacy equivalent to approximately 30 units of subcutaneous calcitonin.

    In plain wordsIn Paget's disease, nasal calcitonin had qualitatively similar effects to injected calcitonin, but needed a higher dose.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableCalcium-lowering route equivalence
    Study

    n: not reported in source

    Comparator
    Subcutaneous calcitonin
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    400 units · intranasal · single doseAs given in this study (human).

    Measurements

    Equivalent subcutaneous dose
    ≈ 30 units
    400 units intranasal

    Source sentences

    Summary
    Four hundred units of calcitonin administered as a nasal spray induced effects qualitatively similar to those seen with subcutaneous calcitonin, with an efficacy equivalent to approximately 30 units of subcutaneous calcitonin.
    2 context sentences
    Summary · context
    We studied the acute effects of intranasal and subcutaneous calcitonin in 40 patients with active Paget's disease of bone.
    Summary · context
    Patients received a single dose of either 400 units of calcitonin delivered as a nasal spray, or 1, 10 or 100 units of subcutaneous calcitonin, or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.